Report Code: 11275 | Available Format: PDF | Pages: 157
Note: This report can also be updated as of date and delivered within 1-2 working days of purchase confirmation
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By industry participant
2.2.1.2 By company type
Chapter 3. Executive Summary
Chapter 4. Pipeline Outlook
4.1 Acne Vulgaris Disease Overview
4.1.1 Signs and Symptoms
4.1.2 Pathophysiology
4.1.3 Diagnosis
4.1.4 Etiology
4.1.5 Treatment
4.1.6 Prognosis
4.2 Key Drivers
4.2.1 Increased early stage drug candidates
4.2.2 Positive Clinical Results
4.2.3 XXXX
4.3 Key Barriers
4.3.1 Topical Route of Administration Causes Low Bioavailability
4.4 Acne Vulgaris Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company
Chapter 5. Acne Vulgaris Epidemiology and Patient Population Forecast to 2023 for 7MM
5.1 U.S.
5.2 U.K.
5.3 France
5.4 Germany
5.5 Italy
5.6 Spain
5.7 Japan
Chapter 6. Acne Vulgaris Therapeutics Pipeline Analysis by Phase (2017)
6.1 Filed
6.1.1 DFD-10
6.1.1.1 Strategic development
6.2 Phase III
6.2.1 KW303
6.2.2 XXXX
6.2.2.1 Clinical trials
6.2.3 XXXX
6.2.4 XXXX
6.2.4.1 Pre-Clinical study
6.2.4.2 Clinical trials
6.2.5 XXXX
6.2.5.1 Clinical trials
6.2.5.2 Strategic development
6.2.6 XXXX
6.2.6.1 Clinical trials
6.2.7 XXXX
6.2.7.1 Clinical trials
6.2.7.2 Clinical results
6.2.8 XXXX
6.2.8.1 Clinical trials
6.2.9 XXXX
6.2.10 XXXX
6.2.10.1 Clinical trials
6.2.11 XXXX
6.2.11.1 Clinical trials
6.2.11.2 Strategic development
6.2.12 XXXX
6.2.12.1 Clinical trials
6.2.12.2 Strategic development
6.2.13 XXXX
6.2.13.1 Clinical trials
6.3 Phase II/III
6.3.1 B 244
6.3.1.1 Clinical trials
6.4 Phase II
6.4.1 Visonac
6.4.1.1 Clinical trials
6.4.2 XXXX
6.4.2.1 Clinical trials
6.4.2.2 Strategic development
6.4.3 XXXX
6.4.3.1 Clinical trials
6.4.4 XXXX
6.4.4.1 Clinical trials
6.4.5 XXXX
6.4.5.1 Clinical trials
6.4.5.2 Strategic development
6.4.6 XXXX
6.4.6.1 Clinical trials
6.4.6.2 Strategic development
6.4.7 XXXX
6.4.7.1 Clinical trials
6.4.8 XXXX
6.4.8.1 Clinical trials
6.4.9 XXXX
6.4.9.1 Clinical trials
6.4.10 XXXX
6.4.10.1 Clinical trials
6.4.11 XXXX
6.4.11.1 Clinical trials
6.4.11.2 Strategic development
6.4.12 XXXX
6.4.12.1 Clinical trials
6.4.13 XXXX
6.4.13.1 Clinical trials
6.4.13.2 Strategic development
6.4.14 XXXX
6.4.14.1 Clinical trials
6.4.15 XXXX
6.4.15.1 Clinical trials
6.4.16 XXXX
6.4.16.1 Clinical trials
6.5 Phase I
6.5.1 XXXX
6.5.1.1 Clinical trials
6.5.2 XXXX
6.5.3 XXXX
6.5.3.1 Clinical trials
6.6 Pre-Clinical
6.6.1 XXXX
6.6.1.1 Pre-Clinical results
6.6.2 XXXX
6.6.3 XXXX
6.6.4 XXXX
6.6.5 XXXX
6.7 Discovery
6.7.1 Acne Vulgaris Vaccine - Origimm
6.7.2 XXXX
6.8 Unknown
6.8.1 Peptide - Helix Biomedix, Inc.
6.8.2 XXXX
6.8.3 XXXX
6.8.4 XXXX
6.8.5 XXXX
6.8.6 XXXX
6.8.7 XXXX
6.8.8 XXXX
Chapter 7. Clinical Trials Analysis
7.1 Clinical Trials, by Region
7.2 Clinical Trials, by Trial Status
Chapter 8. Competitive Landscape
8.1 Key Players Benchmarking for Acne Vulgaris Therapeutics Pipeline
8.2 SWOT Analysis of Acne Vulgaris Therapeutics Pipeline
8.2.1 Strengths
8.2.2 Weaknesses
8.2.3 Opportunities
8.2.4 Threats
Chapter 9. Company Profiles
9.1 AndroScience Corporation
9.1.1 Business Overview
9.1.2 Product and Service Offerings
9.2 XXXX
9.2.1 Business Overview
9.2.2 Product and Service Offerings
9.3 XXXX
9.3.1 Business Overview
9.3.2 Product and Service Offerings
9.4 XXXX
9.4.1 Business Overview
9.4.2 Product and Service Offerings
9.5 XXXX
9.5.1 Business Overview
9.5.2 Product and Service Offerings
Chapter 10. Appendix
10.1 Abbreviations
10.2 Related Reports
LIST OF TABLES
TABLE 1: |
PIPELINE ANALYSIS OF ACNE VULGARIS BY COMPANY (2017) |
TABLE 2: |
ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN 7MM, ‘000 (2016–2023) |
TABLE 3: |
ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN THE U.S., ‘000 (2016–2023) |
TABLE 4: |
ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN U.K., ‘000 (2016–2023) |
TABLE 5: |
ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN FRANCE, ‘000 (2016–2023) |
TABLE 6: |
ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN GERMANY, ‘000 (2016–2023) |
TABLE 7: |
ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN ITALY, ‘000 (2016–2023) |
TABLE 8: |
ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN SPAIN, ‘000 (2016–2023) |
TABLE 9: |
ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN JAPAN, ‘000 (2016–2023) |
TABLE 10: |
DESCRIPTION OF DFD-10 |
TABLE 11: |
DESCRIPTION OF KW303 |
TABLE 12: |
DESCRIPTION OF XXX |
TABLE 13: |
CLINICAL TRIALS OF XXXX |
TABLE 14: |
DESCRIPTION OF XXXX |
TABLE 15: |
DESCRIPTION OF XXXX |
TABLE 16: |
CLINICAL TRIALS OF XXXX |
TABLE 17: |
DESCRIPTION OF XXXX |
TABLE 18: |
CLINICAL TRIALS OF XXXX |
TABLE 19: |
DESCRIPTION OF IDP XXXX |
TABLE 20: |
CLINICAL TRIALS OF XXXX |
TABLE 21: |
DESCRIPTION OF XXXX |
TABLE 22: |
CLINICAL TRIALS OF XXXX |
TABLE 23: |
DESCRIPTION OF XXXX |
TABLE 24: |
CLINICAL TRIALS OF XXXX |
TABLE 25: |
DESCRIPTION OF XXXX |
TABLE 26: |
DESCRIPTION OF XXXX |
TABLE 27: |
CLINICAL TRIALS OF XXXX |
TABLE 28: |
DESCRIPTION OF XXXX |
TABLE 29: |
CLINICAL TRIALS OF XXXX |
TABLE 30: |
DESCRIPTION OF XXXX |
TABLE 31: |
CLINICAL TRIALS OF XXXX |
TABLE 32: |
DESCRIPTION OF XXXX |
TABLE 33: |
CLINICAL TRIALS OF XXXX |
TABLE 34: |
DESCRIPTION OF B 244 |
TABLE 35: |
CLINICAL TRIALS OF B 244 |
TABLE 36: |
DESCRIPTION OF VISONAC |
TABLE 37: |
CLINICAL TRIALS OF VISONAC |
TABLE 38: |
DESCRIPTION OF XXXX |
TABLE 39: |
CLINICAL TRIALS OF XXXX |
TABLE 40: |
DESCRIPTION OF XXXX |
TABLE 41: |
CLINICAL TRIALS OF XXXX |
TABLE 42: |
DESCRIPTION OF XXXX |
TABLE 43: |
CLINICAL TRIALS OF XXXX |
TABLE 44: |
DESCRIPTION OF XXXX |
TABLE 45: |
CLINICAL TRIALS OF XXXX |
TABLE 46: |
DESCRIPTION OF XXXX |
TABLE 47: |
CLINICAL TRIALS OF XXXX |
TABLE 48: |
DESCRIPTION OFXXXX |
TABLE 49: |
DESCRIPTION OF XXXX |
TABLE 50: |
CLINICAL TRIALS OF XXXX |
TABLE 51: |
DESCRIPTION OF XXXX |
TABLE 52: |
DESCRIPTION OF XXXX |
TABLE 53: |
CLINICAL TRIALS OF XXXX |
TABLE 54: |
DESCRIPTION OF XXXX |
TABLE 55: |
CLINICAL TRIALS OF XXXX |
TABLE 56: |
DESCRIPTION OF XXXX |
TABLE 57: |
CLINICAL TRIALS OF XXXX |
TABLE 58: |
DESCRIPTION OF XXXX |
TABLE 59: |
CLINICAL TRIALS OF XXXX |
TABLE 60: |
DESCRIPTION OF XXXX |
TABLE 61: |
CLINICAL TRIALS OF XXXX |
TABLE 62: |
DESCRIPTION OF XXXX |
TABLE 63: |
CLINICAL TRIALS OF XXXX |
TABLE 64: |
DESCRIPTION OF XXXX |
TABLE 65: |
CLINICAL TRIALS OF XXXX |
TABLE 66: |
DESCRIPTION OF XXXX |
TABLE 67: |
CLINICAL TRIALS OF XXXX |
TABLE 68: |
DESCRIPTION OF XXXX |
TABLE 69: |
DESCRIPTION OF XXXX |
TABLE 70: |
DESCRIPTION OF XXXX |
TABLE 71: |
DESCRIPTION OF XXXX |
TABLE 72: |
DESCRIPTION OF XXXX |
TABLE 73: |
DESCRIPTION OF XXXX |
TABLE 74: |
DESCRIPTION OF XXXX |
TABLE 75: |
DESCRIPTION OF ACNE VULGARIS VACCINE - ORIGIMM |
TABLE 76: |
DESCRIPTION OF XXXX |
TABLE 77: |
DESCRIPTION OF PEPTIDE – HELIX BIOMEDIX, INC. |
TABLE 78: |
DESCRIPTION OF XXXX |
TABLE 79: |
DESCRIPTION OF XXXX |
TABLE 80: |
DESCRIPTION OF XXXX |
TABLE 81: |
DESCRIPTION OF XXXX |
TABLE 82: |
DESCRIPTION OF XXXX |
TABLE 83: |
DESCRIPTION OF XXXX |
TABLE 84: |
DESCRIPTION OF XXXX |
TABLE 85: |
ANDROSCIENCE CORPORATION – AT A GLANCE |
TABLE 86: |
XXXX – AT A GLANCE |
TABLE 87: |
XXXX - KEY FACTS |
TABLE 88: |
XXXX– AT A GLANCE |
TABLE 89: |
XXXX – AT A GLANCE |
LIST OF FIGURES
FIG 1: RESEARCH METHODOLOGY
FIG 2: SPLIT OF PRIMARY AND SECONDARY RESEARCH
FIG 3: BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
FIG 4: BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
FIG 5: TOTAL PREVALENT CASES OF ACNE VULGARIS (2016-2023)
FIG 6: NUMBER OF ACNE VULGARIS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
FIG 7: ACNE VULGARIS PIPELINE SPLIT, BY MOLECULE TYPE (2017)
FIG 8: ACNE VULGARIS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)
FIG 9: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN 7MM (2016–2023)
FIG 10: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN THE U.S. (2016–2023)
FIG 11: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN U.K. (2016–2023)
FIG 12: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN FRANCE (2016–2023)
FIG 13: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN GERMANY, (2016–2023)
FIG 14: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN ITALY (2016–2023)
FIG 15: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN SPAIN (2016–2023)
FIG 16: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN JAPAN (2016–2023)
FIG 17: BREAKDOWN OF CLINICAL TRIALS, BY REGION
FIG 18: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
FIG 19: KEY PLAYERS BENCHMARKING
FIG 20: SWOT ANALYSIS
Get a bespoke market intelligence solution
Want a report tailored exactly to your business strategy?
Request CustomizationWant an insight-rich discussion with the report author?
Speak to AnalystOur dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws